The week of 2025-09-22, 18 holders filed a new Schedule 13D and 53 a new Schedule 13G reporting 5% or more of a company, and 0 13D filings stated in Item 4 an intent to influence the company. Open a company for every holder and the purpose each 13D states, quoted.
New Schedule 13D
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2025-09-24 | BlackRock Municipal Credit Alpha Portfolio, Inc. | Bank Of America Corp | 100% | SCHEDULE 13D |
| 2025-09-24 | ZenaTech, Inc. | GG Mars Capital, Inc. | 100% | SCHEDULE 13D |
| 2025-09-26 | Semnur Pharmaceuticals, Inc. | Scilex Holding Company | 79.89% | SCHEDULE 13D |
| 2025-09-25 | Pattern Group Inc. | David K. Wright | 62.6% | SCHEDULE 13D |
| 2025-09-23 | Future FinTech Group Inc. | Shanchun Huang | 48.11% | SCHEDULE 13D |
| 2025-09-22 | Skyline Builders Group Holding Limited | ASP Isotopes Inc. | 36.7% | SCHEDULE 13D |
| 2025-09-23 | Talon Capital Corp. | Talon Capital Sponsor LLC | 25.9% | SCHEDULE 13D |
| 2025-09-23 | Deep Fission, Inc. | Muller Elizabeth | 20.6% | SCHEDULE 13D |
| 2025-09-23 | Bonk, Inc. | Lucky Dog Holdings | 19.99% | SCHEDULE 13D |
| 2025-09-26 | CASI Pharmaceuticals, Inc. | Panacea Innovation Limited | 19.9% | SCHEDULE 13D |
| 2025-09-23 | Deep Fission, Inc. | Muller Richard | 10.6% | SCHEDULE 13D |
| 2025-09-25 | Solana Co | Morehead Daniel Wayne | 9.67% | SCHEDULE 13D |
| 2025-09-22 | NewtekOne Inc | Patriot Financial Partners IV, L.P. | 8.06% | SCHEDULE 13D |
| 2025-09-22 | Sturm Ruger & Co Inc | Beretta Holding S.A. | 7.74% | SCHEDULE 13D |
| 2025-09-25 | LB Pharmaceuticals Inc. | Pontifax Management 4 G.P. (2015) Ltd. | 6.3% | SCHEDULE 13D |
| 2025-09-22 | Highland Opportunities & Income Fund | Dondero James D | 5.2% | SCHEDULE 13D |
| 2025-09-22 | Staar Surgical Co | Yunqi Capital Limited | 5.1% | SCHEDULE 13D |
| 2025-09-23 | Ameriserv Financial Inc | Baird Brent D | 5.1% | SCHEDULE 13D |
New Schedule 13G
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2025-09-26 | Platinum Analytics Cayman Ltd | Huiyi Zheng | 29.27% | SCHEDULE 13G |
| 2025-09-24 | Oxford Lane Capital Corp. | Thomas Philip Majewski | 18.98% | SCHEDULE 13G |
| 2025-09-23 | Mach Natural Resources LP | IKAV General Partner s.a r.l. | 18.2% | SCHEDULE 13G |
| 2025-09-25 | Pioneer Diversified High Income Fund, Inc. | Absolute Investment Advisers, LLC | 14.8% | SCHEDULE 13G |
| 2025-09-25 | Beyond Meat, Inc. | Unprocessed Foods, LLC | 12.5% | SCHEDULE 13G |
| 2025-09-22 | Mach Natural Resources LP | Kayne Anderson Capital Advisors LP | 11.41% | SCHEDULE 13G |
| 2025-09-25 | Pioneer Floating Rate Fund, Inc. | Absolute Investment Advisers, LLC | 11.3% | SCHEDULE 13G |
| 2025-09-24 | C3is Inc. | Wexford Capital LP | 10.23% | SCHEDULE 13G |
| 2025-09-23 | Vor Biopharma Inc. | ForGrowth III PA B.V. | 9.99% | SCHEDULE 13G |
| 2025-09-22 | Bionano Genomics, Inc. | CVI Investments, Inc. | 9.9% | SCHEDULE 13G |
| 2025-09-24 | Bionano Genomics, Inc. | Lind Global Fund III LP | 9.9% | SCHEDULE 13G |
| 2025-09-24 | Netskope, Inc. | SCGE Fund, L.P. | 9.9% | SCHEDULE 13G |
| 2025-09-25 | Vor Biopharma Inc. | Venrock Healthcare Capital Partners III, L.P. | 9.9% | SCHEDULE 13G |
| 2025-09-26 | Lava Therapeutics N.V. | Shay Capital LLC | 9.9% | SCHEDULE 13G |
| 2025-09-26 | Vor Biopharma Inc. | Verve Capital Limited | 9.9% | SCHEDULE 13G |
| 2025-09-22 | Reliance Global Group, Inc. | White Lion Capital, LLC | 9.77% | SCHEDULE 13G |
| 2025-09-22 | Strive, Inc. | Graham Capital Management, L.P. | 9.66% | SCHEDULE 13G |
| 2025-09-26 | Lunai Bioworks Inc. | Laksya Ventures Inc. | 9.6% | SCHEDULE 13G |
| 2025-09-22 | Aethlon Medical Inc | Alumni Capital LP | 9.58% | SCHEDULE 13G |
| 2025-09-23 | Precigen, Inc. | William H. Miller III Living Trust dated April 17, 2017 | 9.2% | SCHEDULE 13G |
| 2025-09-22 | SuperX AI Technology Ltd | Rime Value Oriented Lpf | 9% | SCHEDULE 13G |
| 2025-09-26 | Hanesbrands Inc. | Loews Corporation | 9% | SCHEDULE 13G |
| 2025-09-23 | PMV Pharmaceuticals, Inc. | Tang Capital Management, LLC | 8.9% | SCHEDULE 13G |
| 2025-09-26 | Platinum Analytics Cayman Ltd | Qihong Bao | 8.67% | SCHEDULE 13G |
| 2025-09-25 | SuperX AI Technology Ltd | Qiu Zhongwei | 8.4% | SCHEDULE 13G |
| 2025-09-23 | Carparts.Com, Inc. | Axislink Holding B.V. | 8.05% | SCHEDULE 13G |
| 2025-09-22 | Precipio, Inc. | Leviticus Partners LP | 8% | SCHEDULE 13G |
| 2025-09-24 | Future FinTech Group Inc. | Avondale Capital, LLC | 8% | SCHEDULE 13G |
| 2025-09-24 | SmartKem, Inc. | Lizzio Joseph Christopher | 7.65% | SCHEDULE 13G |
| 2025-09-22 | Gilat Satellite Networks Ltd | Clal Insurance Enterprises Holdings Ltd | 7.3% | SCHEDULE 13G |
| 2025-09-24 | Dfp Holdings Limited | CPN Investment Ltd | 6.86% | SCHEDULE 13G |
| 2025-09-24 | Alignment Healthcare Inc | Qatar Investment Authority | 6.69% | SCHEDULE 13G |
| 2025-09-24 | Eightco Holdings Inc. | Gama Dat Vi Spv, LLC | 6.4% | SCHEDULE 13G |
| 2025-09-22 | Gemini Space Station Inc | Mark W. Yusko | 6.3% | SCHEDULE 13G |
| 2025-09-23 | Pyxis Oncology, Inc. | GordonMD Global Investments LP | 6.2% | SCHEDULE 13G |
| 2025-09-24 | Opendoor Technologies Inc. | Jane Street Group, LLC | 5.9% | SCHEDULE 13G |
| 2025-09-26 | GSR III Acquisition Corp. | Merus Global Investments, LLC | 5.8% | SCHEDULE 13G |
| 2025-09-22 | Pyrophyte Acquisition Corp. II | Linden Advisors LP | 5.7% | SCHEDULE 13G |
| 2025-09-25 | Peabody Energy Corporation | Key Group Long Term Investments LP | 5.6% | SCHEDULE 13G |
| 2025-09-26 | Flutter Entertainment plc | Dart Kenneth Bryan | 5.6% | SCHEDULE 13G |
| 2025-09-24 | Oruka Therapeutics, Inc. | Viking Global Investors LP | 5.5% | SCHEDULE 13G |
| 2025-09-26 | Peabody Energy Corporation | Maverick Capital, Ltd. | 5.5% | SCHEDULE 13G |
| 2025-09-22 | Rezolute, Inc. | Raymond Debbane | 5.4% | SCHEDULE 13G |
| 2025-09-24 | TMC the metals Co Inc. | Brumder William George | 5.4% | SCHEDULE 13G |
| 2025-09-22 | Tango Therapeutics, Inc. | Raymond Debbane | 5.3% | SCHEDULE 13G |
| 2025-09-25 | Forum Markets Inc | Kenneth Griffin | 5.3% | SCHEDULE 13G |
| 2025-09-26 | Wingstop Inc | Lone Pine Capital LLC | 5.3% | SCHEDULE 13G |
| 2025-09-26 | Drilling Tools International Corp | Jeffrey L. Gendell | 5.2% | SCHEDULE 13G |
| 2025-09-23 | Anaptysbio, Inc | Millennium Management LLC | 5.1% | SCHEDULE 13G |
| 2025-09-26 | Cryoport, Inc. | Integrated Core Strategies (US) LLC | 5.1% | SCHEDULE 13G |
| 2025-09-26 | Sequans Communications Sa | Daniel Asher | 5.03% | SCHEDULE 13G |
| 2025-09-26 | Mid Penn Bancorp, Inc. | Bay Pond Partners, L.P. | 5% | SCHEDULE 13G |
| 2025-09-26 | Lineage Cell Therapeutics Inc | Chernett Jorey | 5% | SCHEDULE 13G |
Stated intent
No 13D this week stated an intent to influence the company.
Tools for this story
Each opens in a new tab. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.